## FINAL - September 23, 2021

## MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention Atlanta, Georgia 30329 September 22-23, 2021

AGENDA ITEM	PRESIDER/PRESENTER(s)

Wedne	esday, September 22, 2021	
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair)
		Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
10:15	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	Safety and immunogenicity for a 3rd dose of BNT162b2	Dr. Bill Gruber (Pfizer-BioNTech)
	Immunity and SARS-CoV-2	Dr. Natalie Thornburg (CDC/NCIRD)
11:45	Break	
12:15	Vaccine effectiveness studies in the United States	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Modeling the potential impact of booster doses in nursing	Dr. Rachel Slayton (CDC/NCEZID)
	home residents	
1:45	Break	
2:00	Early safety monitoring for third doses of mRNA vaccines	Dr. Anne Hause (CDC/NCEZID)
	VaST summary	Dr. Keipp Talbot (VaST Chair)
	Work Group summary	Dr. Sara Oliver (CDC/NCIRD)
3:30	Break	
3:45	Pregnancy: Safety monitoring in v-safe	Dr. Christine Olson (CDC/NCEZID)
	Pregnancy: Safety monioring in VSD	Dr. Elyse Kharbanda (HealthPartners Institute)
	Updates on COVID-19 and pregnancy	Dr. Dana Meaney Delman (CDC/NCBDDD)
4:30	Adjourn	
<u>I hursd</u>	lay, September 23, 2021	
	lay, September 23, 2021 Welcome & Introductions	Dr. Grace Lee (ACIP Chair)
		Dr. Grace Lee (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
	Welcome & Introductions	,
12:00	Welcome & Introductions	,
12:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
12:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
12:00 12:15	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
12:00 12:15 12:50	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)
12:00 12:15 12:50	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break  COVID-19 vaccine booster doses: Benefit/risk discussion	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)
12:00 12:15 12:50	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)
12:00 12:15 12:50	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)
12:00 12:15 12:50	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine Clinical considerations	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)
12:00 12:15 12:50 1:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine Clinical considerations Discussion VOTE	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)  Dr. Kathleen Dooling (CDC/NCIRD)
12:00 12:15 12:50 1:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine Clinical considerations Discussion VOTE  COVID-19 vaccine booster doses	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)
12:00 12:15 12:50 1:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine Clinical considerations Discussion VOTE	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)  Dr. Kathleen Dooling (CDC/NCIRD)
12:00 12:15 12:50 1:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment  Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine Clinical considerations Discussion  VOTE  COVID-19 vaccine booster doses Adjourn	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)  Dr. Kathleen Dooling (CDC/NCIRD)
12:00 12:15 12:50 1:00	Welcome & Introductions  Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Public Comment Break  COVID-19 vaccine booster doses: Benefit/risk discussion Evidence to Recommendation Framework: Booster doses of Pfizer-BioNTech COVID-19 vaccine Clinical considerations Discussion VOTE  COVID-19 vaccine booster doses	Dr. Amanda Cohn (ACIP Executive Secretary, CDC)  Dr. Matthew Daley (ACIP, WG Chair)  Dr. Megan Wallace (CDC/NCIRD)  Dr. Sara Oliver (CDC/NCIRD)  Dr. Kathleen Dooling (CDC/NCIRD)

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases

## FINAL - September 23, 2021

OIDP Office of Infectious Disease and HIV/AIDS Policy SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

WG Work Group

WHO World Health Organization VE Vaccine Effectiveness